About
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies.
Our Vision
Imagine a future where people suffering from serious, rare skin diseases—and the physicians that treat them—have more options than ever before.
Our vision, supported by our mission of serving patients, is to become the leading rare disease biopharmaceutical company focused on developing and (if approved) commercializing novel therapies for serious, rare skin diseases for which there are no approved therapies.
Our Team
Leadership
Board of Directors
Medical and Scientific Advisory Board
Keith Choate, M.D., Ph.D.
Professor and Chair, Dermatology
Yale School of Medicine
Dirk Elston, M.D.
Professor and Chair, Dermatology and Dermatologic Surgery
Medical University of South Carolina
Mike Kelly, M.D., Ph.D.
Pediatric Hematology Oncology
Cleveland Clinic
Amy S. Paller, M.D.
Chair, Department of Dermatology · Director, Skin Biology and Diseases Resource-Based Center
Walter J. Hamlin Professor of Dermatology
Northwestern Medicine
Vishal Patel, M.D., FAAD, FACMS
Associate Professor of Dermatology • Director, Cutaneous Oncology Program
The George Washington University
Joyce Teng, M.D., Ph.D.
Professor of Dermatology
Stanford University
James Treat, M.D.
Professor of Clinical Pediatrics and Dermatology
Children’s Hospital of Philadelphia
Michael H. White, MD, MSc
Aflac Cancer and Blood Disorders Center
Children's Healthcare of Atlanta